^
    Back
    Association details:
    Biomarker:EGFR L861X
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer

    Excerpt:
    ...- Tumor with an activating mutation of EGF-R (deletion of exon 19 or L858R, L861x, or G719x mutation)...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1327P - First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)

    Published date:
    10/16/2023
    Excerpt:
    This is a multicentered Canadian phase II investigator-initiated study of (cohort A) osimertinib in the third-line (3L) rechallenge of patients with EGFR+ aNSCLC, following 1L treatment with osimertinib and 2L therapy with platinum pemetrexed chemotherapy; and (cohort B) 1L osimertinib in patients with uncommon EGFR mutations (exon 20 insertions are not permitted)....Osimertinib appears to be highly active and well tolerated in patients with the more frequent ‘uncommon’ EGFR mutations (G719X, L861X, and S768I).
    Trial ID:
    OCELOT